Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy-Reference-Cited by-同舟云学术

Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy

Published:2013-08-05 Issue:8 Volume:8 Page:e71356
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Yamashita Fumie,Azuma Koichi,Yoshida Tsukasa,Yamada Kazuhiko,Kawahara Akihiko,Hattori Satoshi,Takeoka Hiroaki,Zaizen Yoshiaki,Kawayama Tomotaka,Kage Masayoshi,Hoshino Tomoaki

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference25 articles.

1. Cancer burden in the year 2000: the global picture;DM Parkin;Eur J Cancer,2001

2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;TJ Lynch;N Engl Med,2004

3. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;JG Paez;Science,2004

4. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;M Maemondo;N Engl J Med,2010

5. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial;T Mitsudomi;Lancet Oncol,2010

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tobacco Smoking and Survival Following a Diagnosis with Ovarian Cancer;Cancer Epidemiology, Biomarkers & Prevention;2022-07-01

2. Meta-Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer;Evidence-Based Complementary and Alternative Medicine;2020-04-30

3. EGFR exon 19‐deletion aberrantly regulate ERCC1 expression that may partly impaired DNA damage repair ability in non‐small cell lung cancer;Thoracic Cancer;2019-12-25

4. Epidermal growth factor receptor mutation subtype has differential effects on adjuvant chemotherapy for resected adenocarcinoma pathological stages�II‑III;Oncology Letters;2019-11-04

5. Precision medicine in oncology: what is it exactly and where are we?;Personalized Medicine;2018-09